tradingkey.logo
tradingkey.logo
Search

Moderna Inc

MRNA
Add to Watchlist
223.370USD
-7.980-3.45%
Close 11-13 16:00(ET)
89.18BMarket Cap
LossP/E TTM
After-hours 19:46 (ET)216.020USD-7.115-3.19%

Today

-3.45%

5 Days

-12.12%

1 Month

-5.55%

6 Months

+355.49%

Year to Date

+657.44%

1 Year

+801.78%

Key Figures

224.900Open
245.370High
1.54MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.39%Turnover Ratio
231.350Prev. Close
221.740Low
346.64MTurnover
LossP/E Static
13.19P/B
0.00%Div Yield TTM
-26.41%ROA
280.80052wk High
50.52Volume Ratio
-3.56BNet Profit
399.24MShares
-8.1390EPS TTM
1.06Beta
-36.56%ROE
22.28052wk Low
10.21%Amplitude
79.89%Gross Margin
89.18BMarket Cap
1.63Reward/Risk
12.28%Risk Rate
Recent
Analysis
Earnings
Transcripts
Moderna Inc Stock (MRNA) Moved Down by 5.50% on Nov 12: Drivers Behind the Movement

• Moderna shares dropped following profit-taking after the recent Analyst Day presentation. • High capital intensity for oncology pivot raised investor concerns over cash burn. • Strong prior stock gains and lack of near-term catalysts triggered selling.

TradingKeyThu, Nov 12
Moderna Inc Stock (MRNA) Moved Down by 4.50% on Nov 10: Drivers Behind the Movement

• Moderna shares declined amid skepticism over respiratory vaccine commercial rollouts and competition. • High R&D spending and pipeline investments raised concerns over operational profitability. • Technical indicators show a MACD buy signal and neutral RSI condition.

TradingKeyTue, Nov 10
Eli Lilly and Co Stock (LLY) Moved Up by 3.09% on Nov 9: Facts Behind the Movement

• Eli Lilly reported an annual revenue of $65.18B and net profit of $20.64B. • Tirzepatide portfolio expansion and improved manufacturing capacity drive strong institutional investor sentiment. • Technical indicators including MACD and Williams %R currently suggest a buy signal.

TradingKeyMon, Nov 9
Moderna Inc Stock (MRNA) Moved Up by 9.76% on Nov 6: A Full Analysis

• Moderna reported unexpected third-quarter profitability driven by strong Spikevax vaccine demand. • Management upgraded full-year revenue guidance amid ongoing operational discipline and cost-containment. • Late-stage oncology pipeline progress and constructive regulatory updates supported positive sentiment.

TradingKeyFri, Nov 6
Health Canada Authorizes Moderna’s mFLUSIVA and mCOFLU Vaccines

Health Canada authorized Moderna’s mFLUSIVA influenza vaccine and mCOFLU combined influenza and COVID-19 vaccine for adults aged 50 and older.

TradingKeyFri, Nov 6
Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.61% on Nov 3: Drivers Behind the Movement

• Vertex missed EPS expectations despite higher year-over-year third-quarter revenue. • Operating expenses and Crinetics integration costs pressured third-quarter profitability. • Management raised full-year revenue guidance incorporating the Crinetics acquisition.

TradingKeyTue, Nov 3

Moderna Inc's Score

0.00vs previous score
Forecast6.25
Financial Health5.82
Technical5.63
Valuation Dimensions9.58
Institutional Confidence7.00
Risk Assessment1.89

Media Coverage

Coverage Level

50°C

Very Low
Very High
Positive+

Analyst Rating

Strong Buy
Buy
Hold
Sell
Strong Sell
HoldCurrent Rating
143.153Target Price
-35.44%Upside Space
Current Rating2026-112026-102026-092026-082026-072026-062026-052026-04
Strong Buy22000000
Buy44444433
Hold1415171717171919
Sell33233222
Strong Sell10111111

Moderna Inc Technical Analysis

1m
5m
15m
30m
1h
2h
4h
D
W
M
1m
5m
15m
D
Technical Indicators
Sell
Summary
Sell
Moving Average
Neutral

Moderna Inc Latest Earnings Call Transcripts

Moderna (MRNA) Q3 2026 Earnings Call: Revenue Up 29%, Outlook Raised

Moderna’s Q3 2026 earnings call covered 29% revenue growth, positive Phase III intismeran data, stronger cash levels and raised full-year guidance.

Financial Indicators

Currency: USD
Quarterly
Quarterly
Annual
Relevant data have not been disclosed by the company yet.
Currency: USD
Quarterly
Quarterly
Annual
Relevant data have not been disclosed by the company yet.

Earnings

Next reporting date
--
Reporting Period
2026Q3
Earnings / Forecast
0.40/-1.25
Revenue / Forecast
1.31B/885.05M

Moderna Inc Profile

SectorPharmaceuticals
Ticker SymbolMRNA
Number of employees5800
CountryUnited States of America

Ownership

ShareholdersProportion
Fidelity Management & Research Company LLC6.74%
Vanguard Capital Management, LLC5.76%
BlackRock Institutional Trust Company, N.A.5.30%
Baillie Gifford & Co.5.04%
Shareholder TypesProportion
Investment Advisor45.49%
Investment Advisor/Hedge Fund14.13%
Hedge Fund10.11%
Corporation4.56%

FAQs

What is the current price of Moderna Inc (MRNA)?

The current price of Moderna Inc (MRNA) is 223.37.

What is the symbol of Moderna Inc?

The ticker symbol of Moderna Inc is MRNA.

What is the 52-week high of Moderna Inc?

The 52-week high of Moderna Inc is 280.80.

What is the 52-week low of Moderna Inc?

The 52-week low of Moderna Inc is 22.28.

What is the market capitalization of Moderna Inc?

The market capitalization of Moderna Inc is 89.18B.

Is Moderna Inc (MRNA) currently rated as Buy, Hold, or Sell?

According to analysts, Moderna Inc (MRNA) has an overall rating of signal_hold, with a price target of 143.15.

What is the Earnings Per Share (EPS TTM) of Moderna Inc (MRNA)?

The Earnings Per Share (EPS TTM) of Moderna Inc (MRNA) is -8.14.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.